Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development
Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc.
Immunome Inc. (IMNM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 7,034,952 | $151,110,769 | +46% | 0.17% |
| 2. | Redmile Group Jeremy Green | 5,718,385 | $122,830,910 | +14% | 9.05% |
| 3. | Enavate Sciences James Boylan | 4,768,583 | $102,429,163 | 20.21% | |
| 4. | Driehaus Capital Richard Driehaus | 3,705,974 | $79,604,322 | +433% | 0.54% |
| 5. | EcoR1 Capital Oleg Nodelman | 2,855,590 | $61,338,073 | -31% | 2.78% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.67 | 25,450 | $500,601.50 | 690,704 | 2026-03-27 | Filing | |
| $21.55 | 1,000 | $21,550.00 | 38,415 | 2026-03-11 | Filing | |
| $22.12 | 1,000 | $22,120.00 | 37,415 | 2026-03-10 | Filing | |
| $21.15 | 4,729 | $100,018.35 | 665,254 | 2025-12-30 | Filing | |
| $20.48 | 7,278 | $149,053.44 | 860,525 | 2025-12-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.64 | 9,438 | $204,238.32 | 22,000 | 2026-04-02 | Filing | |
| $22.48 | 1,344 | $30,213.12 | 54,037 | 2026-04-02 | Filing | |
| $21.91 | 63,656 | $1,394,702.96 | 55,381 | 2026-04-02 | Filing | |
| $20.65 | 28,200 | $582,330.00 | 341,147 | 2026-03-23 | Filing | |
| $20.47 | 36,800 | $753,296.00 | 369,347 | 2026-03-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,549,716 | $355,487,900 | 0.02% | |
| 2. | 7,594,996 | $163,140,515 | 0% | |
| 3. | 6,038,414 | $129,705,133 | 0% | |
| 4. | 4,685,441 | $100,643,273 | 0.08% | |
| 5. | 3,868,000 | $83,084,640 | 0% |
News See All
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?
On December 15, Immunome, Inc. (NASDAQ:IMNM) shared positive topline results from the Phase 3 RINGSIDE trial, demonstrating an improved survival rate without progression, when compared with a placebo.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Jim Cramer Offered Insights on These 16 Stocks
“I need you to understand what makes my approach different from the conventional wisdom. It's all rooted in the sales and trading I did for 20 years before Mad Money started.
Hedge Fund and Insider Trading News: Anthony Scaramucci, Michael Burry, Bill Miller, Brevan Howard Asset Management, Engine No. 1, Bright Health Group Inc (BHG), J2 Global Inc (JCOM), and More
SkyBridge Capital’s Anthony Scaramucci is stepping up his firm’s move into the cryptocurrency world, announcing on Monday a partnership aimed at expanding into the blockchain universe.
Hedge Fund Resource Center